Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 8051 to 8100 of 8131 results

  1. Marstacimab for treating severe haemophilia A or moderately severe to severe haemophilia B in people 12 years and over [ID6342]

    In development [GID-TA11397] Expected publication date: TBC

    Technology appraisal guidance
    In development

  2. Pembrolizumab with chemotherapy for treating HER2-negative advanced gastric or gastro-oesophageal junction adenocarcinoma [ID4030]

    In development [GID-TA11039] Expected publication date: 21 August 2024

    Technology appraisal guidance
    In development

  3. Ataluren for treating Duchenne muscular dystrophy with a nonsense mutation in the dystrophin gene for babies 6 months and over to children under 2 years TS ID 11774

    Discontinued [GID-TA11124]

    Technology appraisal guidance
    Discontinued

  4. Bimekizumab for treating moderate to severe hidradenitis suppurativa [ID6134]

    In development [GID-TA11045] Expected publication date: 20 November 2024

    Technology appraisal guidance
    In development

  5. Imlunestrant for treating oestrogen receptor-positive HER2-negative advanced breast cancer after endocrine therapy ID6373

    In development [GID-TA11439] Expected publication date: TBC

    Technology appraisal guidance
    In development

  6. Liposomal bupivacaine for treating postoperative pain [ID3799]

    The topic was stopped after scoping, this means the topic will not proceed to a Technology Appraisal   ...

    Technology appraisal guidance
    Topic selection

  7. Amivantamab with lazertinib for untreated EGFR mutation-positive advanced non-small-cell lung cancer [ID6256]

    Awaiting development [GID-TA11279] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Crovalimab for treating paroxysmal nocturnal haemoglobinuria [ID6140]

    In development [GID-TA11062] Expected publication date: 30 October 2024

    Technology appraisal guidance
    In development

  9. Optical Coherence Tomography to guide percutaneous coronary intervention

    In development [GID-IPG10394] Expected publication date: TBC

    Interventional procedures guidance
    In development

  10. Cemiplimab with platinum-based chemotherapy for untreated advanced non-small-cell lung cancer [ID3949]

    In development [GID-TA10907] Expected publication date: TBC

    Technology appraisal guidance
    In development

  11. Surgical Insertion of a Catheter based intravascular microaxial blood pump

    Register an interest in this interventional procedure   ...

    Interventional procedures guidance
    Topic selection

  12. Linzagolix for treating pain caused by endometriosis [ID6357]

    In development [GID-TA11376] Expected publication date: TBC

    Technology appraisal guidance
    In development

  13. Single-step scaffold insertion for repairing symptomatic chondral knee defects

    Awaiting development [GID-IPG10364] Expected publication date: 17 September 2024

    Interventional procedures guidance
    Awaiting development

  14. Single-step scaffold insertion for repairing symptomatic chondral knee defects: interventional procedure consultation

    We are listening to your views on this Interventional procedures guidance. Comments close 22 May 2024.

    Interventional procedures guidance
    In consultation

  15. Elafibranor for treating primary biliary cholangitis [ID6331]

    In development [GID-TA11378] Expected publication date: TBC

    Technology appraisal guidance
    In development

  16. Phrenic nerve pacing for ventilator-dependent high cervical spinal cord injury

    Awaiting development [GID-IPG10367] Expected publication date: 15 August 2024

    Interventional procedures guidance
    Awaiting development

  17. Phrenic nerve pacing for congenital central hypoventilation syndrome

    Awaiting development [GID-IPG10317] Expected publication date: 15 August 2024

    Interventional procedures guidance
    Awaiting development

  18. Caval valve implantation for tricuspid regurgitation

    Awaiting development [GID-IPG10344] Expected publication date: 21 August 2024

    Interventional procedures guidance
    Awaiting development

  19. One-piece closed bags for adults with a colostomy: Late Stage Assessment

    In development [GID-HTE10045] Expected publication date: TBC

    Health technology evaluations
    In development

  20. Rehabilitation for chronic neurological disorders including acquired brain injury

    In development [GID-NG10181] Expected publication date: 21 May 2025

    NICE guideline
    In development

  21. Blinatumomab with chemotherapy for consolidation treatment of Philadelphia-chromosome-negative CD19-positive B-precursor acute lymphoblastic leukaemia with no measurable residual disease ID6405

    In development [GID-HTE10035] Expected publication date: TBC

    Health technology evaluations
    In development

  22. Falls: assessment and prevention in older people and people 50 and over at higher risk (update)

    In development [GID-NG10228] Expected publication date: 26 March 2025

    NICE guideline
    In development

  23. Idebenone for treating visual impairment in Leber's hereditary optic neuropathy in people 12 years and over [ID547]: draft guidance

    We are listening to your views on this Technology appraisal guidance. Comments close 16 May 2024.

    Technology appraisal guidance
    In consultation

  24. Blinatumomab with chemotherapy for consolidation treatment of Philadelphia-chromosome-negative CD19-positive B-precursor acute lymphoblastic leukaemia with no measurable residual disease ID6405: draft scope consultation

    We are listening to your views on this Health technology evaluation. Comments close 23 May 2024.

    Health technology evaluation
    In consultation

  25. Linzagolix for treating moderate to severe symptoms of uterine fibroids [ID6190]

    In development [GID-TA11131] Expected publication date: TBC

    Technology appraisal guidance
    In development

  26. Pembrolizumab for adjuvant treatment of hepatocellular carcinoma [ID3994]

    Awaiting development [GID-TA10895] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  27. Somapacitan for treating growth hormone deficiency in children [ID6178]

    In development [GID-TA11153] Expected publication date: TBC

    Technology appraisal guidance
    In development

  28. Atogepant for preventing migraine [ID5090]

    In development [GID-TA10992] Expected publication date: 15 May 2024

    Technology appraisal guidance
    In development

  29. Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people aged up to 25 years (MA review of TA554) [ID6290]

    In development [GID-TA11381] Expected publication date: 15 May 2024

    Technology appraisal guidance
    In development

  30. Cabotegravir for preventing HIV-1 in adults and young people [ID6255]

    In development [GID-TA11304] Expected publication date: 13 November 2024

    Technology appraisal guidance
    In development

  31. Leadless cardiac pacemaker implantation for bradyarrhythmias

    Awaiting development [GID-IPG10340] Expected publication date: TBC

    Interventional procedures guidance
    Awaiting development

  32. Maternal and child nutrition

    In development [GID-NG10191] Expected publication date: 13 November 2024

    NICE guideline
    In development

  33. Selective internal radiation therapy with QuiremSpheres for treating unresectable advanced hepatocellular carcinoma (Partial review of TA688) [ID6376]

    In development [GID-TA11471] Expected publication date: 03 July 2024

    Technology appraisal guidance
    In development

  34. CYP2C19 genotype testing to guide clopidogrel use after ischaemic stroke or transient ischaemic attack

    In development [GID-DG10054] Expected publication date: 10 July 2024

    Diagnostics guidance
    In development

  35. Direct skeletal fixation of limb or digit prostheses using intraosseous transcutaneous implants

    In development [GID-IPG10351] Expected publication date: 13 November 2024

    Interventional procedures guidance
    In development

  36. Pitolisant for treating narcolepsy in children and young people 6 to 17 years ID6353

    In development [GID-TA11394] Expected publication date: TBC

    Technology appraisal guidance
    In development

  37. Acute kidney injury: prevention, detection and management - Assessing risk factors for acute kidney injury in adults having iodine-based contrast media

    In development [GID-NG10410] Expected publication date: 16 October 2024

    NICE guideline
    In development

  38. Hydromethylthionine mesylate for treating mild cognitive impairment or mild or moderate dementia caused by Alzheimer's disease ID6343

    In development [GID-TA11379] Expected publication date: TBC

    Technology appraisal guidance
    In development

  39. Suspected sepsis: recognition, diagnosis and early management

    In development [GID-NG10412] Expected publication date: 13 August 2025

    NICE guideline
    In development

  40. Dostarlimab with platinum-based chemotherapy for treating advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency (MA review of TA963) [ID6426]

    Awaiting development [GID-TA11536] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  41. Retifanlimab with chemotherapy for previously untreated metastatic non-small-cell lung cancer ID 6436

    Awaiting development [GID-TA11532] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  42. Setmelanotide for treating obesity and hyperphagia in Bardet-Biedl syndrome [ID3947]

    In development [GID-TA10834] Expected publication date: 22 May 2024

    Technology appraisal guidance
    In development

  43. Zilucoplan for treating antibody positive generalised myasthenia gravis [ID4008]

    In development [GID-TA11096] Expected publication date: 07 August 2024

    Technology appraisal guidance
    In development

  44. Rozanolixizumab for treating antibody-positive generalised myasthenia gravis [ID5092]

    In development [GID-TA10994] Expected publication date: TBC

    Technology appraisal guidance
    In development

  45. Voxelotor for treating sickle cell disease [ID1403]

    In development [GID-TA10505] Expected publication date: 12 June 2024

    Technology appraisal guidance
    In development

  46. Olaparib for treating BRCA mutation-positive HER2-negative metastatic breast cancer after chemotherapy (Review of TA762) [ID6336]

    In development [GID-TA11514] Expected publication date: 25 September 2024

    Technology appraisal guidance
    In development

  47. Fenfluramine for treating seizures associated with Lennox–Gastaut syndrome in people 2 years and over [ID1651]

    In development [GID-TA10653] Expected publication date: 22 May 2024

    Technology appraisal guidance
    In development

  48. Isatuximab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma [Review of TA658] [ID4067]

    In development [GID-TA10979] Expected publication date: 26 June 2024

    Technology appraisal guidance
    In development

  49. Obesity: clinical assessment and management (QS update)

    In development [GID-QS10183] Expected publication date: TBC

    Quality standard
    In development

  50. Obesity: prevention and lifestyle management (QS update)

    In development [GID-QS10184] Expected publication date: TBC

    Quality standard
    In development